Navigation Links
TGen-Scottsdale Healthcare clinical trial results for BIND-014 presented at AACR 2013

WASHINGTON, D.C. April 9, 2013 The nanoparticle drug BIND-014 is effective against multiple solid tumors, according to results generated by the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare, and presented today at the American Association for Cancer Research (AACR) Annual Meeting 2013.

Data for the study was generated at the Virginia G. Piper Cancer Center Clinical Trials, a partnership of TGen and Scottsdale Healthcare.

Dr. Daniel Von Hoff, TGen Physician-In-Chief and Chief Scientific Officer of Scottsdale Healthcare's Clinical Research Institute, will present A Phase 1 Study of BIND-014, a PSMA-targeted Nanoparticle Containing Docetaxel, in Patients with Refractory Solid Tumors during an AACR session at 1 p.m. EDT today at the Washington, D.C., Convention Center, Room 146.

Dr. Von Hoff, the study's Principal Investigator, will present complete Phase 1 clinical data of BIND-014, which is produced by BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM. BIND-014 is the company's lead drug candidate.

In 28 patients with advanced or metastatic solid tumors, BIND-014 with its targeted docetaxel Accurin was shown to be generally safe and well-tolerated at the established maximum dose of 60 mg/m2. BIND-014 showed encouraging signs of anti-tumor activity, including one complete response, three partial responses and five patients with stable disease lasting at least four, 12-week-plus cycles. In addition, the pharmacokinetic (PK) profile of BIND-014 was substantially different from the published PK of conventional docetaxel.

"This Phase 1 trial has successfully established the safety and tolerability profile and maximum tolerated dose of BIND-014 in patients with advanced or metastatic solid tumor cancers," said Dr. Von Hoff, F.A.C.P., TGen's Distinguished Professor. "There is a critical need for targeted treatment options for patients with difficult-to-treat solid tumors, and we look forward to further evaluating the potential of BIND-014 in patients with specific solid tumor types in the near future."

"In addition to confirming the safety, tolerability and maximum tolerated dose of BIND-014, these data also provide encouraging signs of anti-tumor activity in a variety of solid tumors," said Dr. Gregory Berk, Chief Medical Officer of BIND Therapeutics. "Based on these data, BIND is moving expeditiously to advance BIND-014 into multiple Phase 2 clinical trials in 2013 including non-small cell lung cancer, prostate cancer and bladder cancer."

BIND-014 represents the first targeted and programmable Accurin nanomedicine to reach the clinic from BIND's proprietary drug development platform, which creates targeted therapeutics designed to accumulate at the site of disease for high drug concentration and maximum therapeutic effect. BIND-014 employs a combination of a targeted biodegradable nanoparticle and docetaxel, a well-established chemotherapy agent.

Dr. Von Hoff's presentation of BIND-014 is consistent with previously reported preliminary observations in which safety, tolerability and efficacy in multiple tumor types was demonstrated:

  • BIND-014 was generally safe and well-tolerated with transient and manageable neutropenia as the dose limiting toxicity. Minimal neuropathy, mucositis, fluid retention, rash, and nail changes were observed.

  • Established the maximum tolerated dose of 60 mg/m2 when administering BIND-014 on a once every 3 week (Q3W) schedule.

  • Evidence of anti-tumor activity was shown with BIND-014 at 60mg/m2 in nine out of the 28 patients treated, ranging from one complete response (cervical cancer), three partial responses (non-small cell lung cancer, prostate and ampullary) and five patients with stabilization of disease lasting at least four cycles (> 12 weeks; pancreatic, colorectal, gall bladder, tonsillar and anal cancer).

  • The PK profile of BIND-014, characterized by prolonged and elevated encapsulated docetaxel levels, was highly differentiated from published PK of conventional docetaxel.

This clinical study was conducted at the Virginia G. Piper Cancer Center at Scottsdale Healthcare in Scottsdale, Arizona, in collaboration with Phoenix-based TGen, the Scottsdale Healthcare Research Institute, Karmanos Cancer Institute in Detroit, Marin Specialty Care in Greenbrae, Calif., and the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center.


Contact: Steve Yozwiak
The Translational Genomics Research Institute

Related biology technology :

1. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
2. Bayer HealthCares Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon
3. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
4. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
5. Sequenom Announces Participation at the 23rd Annual Piper Jaffray Healthcare Conference
6. SuperNova Diagnostics® to Present at the 23rd Annual Piper Jaffray Healthcare Conference in New York City
7. diaDexus, Inc. to Present at the Canaccord Genuity Healthcare Conference
8. ViroPharma to Participate in Two December Healthcare Investor Conferences
9. Celebrating 65 Years of Providing Superior Healthcare Products, Mission Pharmacal Continues to Thrive
10. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
11. Uroplasty to Present at the Oppenheimer 22nd Annual Healthcare Conference
Post Your Comments:
(Date:6/27/2016)... -- Alex,s Lemonade Stand Foundation (ALSF), a leading national childhood ... state-of-the-art bioinformatics lab, using ,big data, to advance the ... Liz Scott , co-executive director of ALSF and ... Washington, D.C. , hosted by Vice ... of pediatric cancer research and awareness. ...
(Date:6/27/2016)... 2016  Global demand for enzymes is forecast ... to $7.2 billion.  This market includes enzymes used ... biofuel production, animal feed, and other markets) and ... Food and beverages will remain the largest market ... of products containing enzymes in developing regions.  These ...
(Date:6/27/2016)... , June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... advised by its major shareholders, Clean Technology Fund I, ... United States based venture capital funds which ... Biorem (on a fully diluted, as converted basis), that ... of their entire equity holdings in Biorem to TUS ...
(Date:6/27/2016)... -- Sequenom, Inc. (NASDAQ: SQNM ), a life ... development of innovative products and services, announced today that ... denied its petition to review decisions by ... Patent No. 6,258,540 (",540 Patent") are not patent eligible ... Court,s Mayo Collaborative Services v. Prometheus Laboratories decision.  In ...
Breaking Biology Technology:
(Date:6/27/2016)... Research and Markets has announced the addition of the "Biometrics ... The report forecasts the biometrics market ... CAGR of 12.28% during the period 2016-2020. The ... inputs from industry experts. The report covers the market landscape and ... a discussion of the key vendors operating in this market. ...
(Date:6/22/2016)... BETHESDA, Md. , June 22, 2016  The American ... by Trade Show Executive Magazine as one of ... Summit on May 25-27 at the Bellagio in ... based on the highest percentage of growth in each of ... number of exhibiting companies and number of attendees. The 2015 ...
(Date:6/22/2016)... LOS ANGELES , June 22, 2016 ... of identity management and verification solutions, has ... cutting edge software solutions for Visitor Management, ... ® provides products that add functional ... The partnership provides corporations and venues with ...
Breaking Biology News(10 mins):